Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 57s
Articles
Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians Different from Caucasians?
Citation:
European Cardiology Review 2018;13(2):112–4.
- Views:
259
- Downloads:
0
Characteristics of Lipid Profile of LPL Deficiency in Japan – Comparison with Non-LPL Deficiency
Citation:
European Cardiology Review 2018;13(2):132.
- Views:
67
- Downloads:
0
Guest Editorial: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9
Citation:
European Cardiology Review 2018;13(1):7–8.
- Views:
137
- Downloads:
0
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors
Citation:
European Cardiology Review 2018;13(1):9–13.
- Views:
311
- Downloads:
0